Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2024 | Intracranial CD1c/CD141 myeloid dendritic cells with ipilimumab & nivolumab in high-grade glioma

Bart Neyns • 13 Sep 2024
ESMO 2024
Brain Tumor Glioma Antibodies Checkpoint Inhibitors Ipilimumab Nivolumab

Bart Neyns, MD, PhD, Universitair Ziekenhuis Brussel, Brussels, Belgium, discusses findings from a Phase I trial (NCT03233152) of intracranial administration of nivolumab, ipilimumab, and autologous myeloid dendritic cells (myDC) in patients with recurrent high-grade glioma (rHGG) following tumor resection. The study found that this approach is safe and well-tolerated, warranting further studies. This interview took place at the European Society for Medical Oncology (ESMO) 2024 Congress in Barcelona, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Bart Neyns

The rationale for dendritic cell therapy in recurrent glioblastoma
2:02
The rationale for dendritic cell therapy in recurrent glioblastoma
Bart Neyns • 13 Sep 2024
Safety of intracranial CD1c/CD141 and checkpoint inhibitors in rHGG
2:12
Safety of intracranial CD1c/CD141 and checkpoint inhibitors in rHGG
Bart Neyns • 13 Sep 2024

Related Videos

MTAP deletions and co-mutational landscape in primary CNS tumors via WGS
2:37
MTAP deletions and co-mutational landscape in primary CNS tumors via WGS
Martin Hojgaard • 29 May 2026
What does the future hold for live cell vaccines in treating brain tumors?
1:25
What does the future hold for live cell vaccines in treating brain tumors?
David Giles • 13 Mar 2026
The benefits of peripheral cancer vaccines for glioblastoma immunotherapy
1:11
The benefits of peripheral cancer vaccines for glioblastoma immunotherapy
David Giles • 13 Mar 2026
Engineering principles for effective glioblastoma vaccine development
1:02
Engineering principles for effective glioblastoma vaccine development
David Giles • 13 Mar 2026
The content of VJOncology is intended for healthcare professionals